Seattle Genetics was founded for the purpose of publishing research. Clay Siegall is one of the founders of the 1998 founded company. He is chairman of the company’s board of directors. Apart from serving as chair, he is also responsible for the day to day management of the company as its CEO. Since its founding and under his able leadership, the company has raised $1.2 billion which is supposed to assist in research. The funds have been wholly sourced from America’s private sector.
Seattle Genetics works towards the development of antibody medication. The passion with which the company operates earned it the FDA carte blanche to develop ADCENTRS: a drug. This drug is today being used around the world in over 60 nations. In order to distribute the product well, Siegall decided to partner with Takeda Pharmaceuticals. This partnership continues to hold and Seattle Genetics is able to distribute its product to those areas it is most needed.
Siegall’s work has been recognized by his former University: University of Maryland. He has the alumnus of the year award from this university to show. Clay has also received the ‘Ernest & Young Entrepreneurship of the year Award’. His academic work and research is widely read and quoted by scholars and students in his field.
Clay Siegall’s undergraduate studies were in zoology at the University of Maryland. He later went back for a master’s degree before his crowning moment at George Washington University, where he graduated with a Ph.D. This later degree was in genetics.
Clay Siegall has always enjoyed reading. He has also taken to research. With this combination, it is no wonder that he blogs. In one of his posts he has discouraged solitary confinement in penitentiaries saying that it amounts to psychological torture. Scientists, according to Siegall have criticized this method of disciplining unruly inmates since it has far reaching negative ramifications. In another post, Clay points out that brain damage is likely to occur in combatants working with heavy firing machines. Although it is yet to be confirmed, he insists that it would be better to err on the side of caution.